Context• Drug repurposing is a relevant approach during the COVID-19 pandemic, because
development of new drugs is time-consuming and costly, and the safety of new drugs is …

The coronavirus disease (COVID-19) pandemic has affected an estimated 16 million
persons and caused 0.6 million deaths worldwide by September 2020. The pandemic has …

COVID-19 has now been affirmedpandemic and novel therapies are immediatelydesirable
as we arrive astageoutside containment. Because COVID-19 is now becoming pandemic …

Traditional drug development and discovery has not kept pace with threats from emerging
and re-emerging diseases such as Ebola virus, MERS-CoV and more recently, SARS-CoV …

The recent outbreak of Coronavirus disease (COVID-19), first in Eastern Asia and then
essentially across the world has been declared a pandemic by the WHO. COVID-19 is …

Despite advances in drug discovery, viral infections remain a major challenge for scientists
across the globe. The recent pandemic of COVID-19 (coronavirus disease 2019), caused by …

COVID-19 is a clinical outcome of viral infection emerged due to strain of beta coronavirus
which attacks the type-2 pneumocytes in alveoli via angiotensin-converting enzyme 2 …

COVID-19 may lead to severe respiratory distress syndrome and high risk of death in some
patients. So far (January 2021), only the antiviral remdesivir has been approved, although …

COVID-19 has now been declared a pandemic and new treatments are urgently needed as
we enter a phase beyond containment. Developing new drugs from scratch is a lengthy …

The COVID-19 pandemic created a large, sudden unmet public health need for rapid access
to safe and effective treatments. Against this backdrop, policy makers and researchers have …